Compare MWH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWH | SRRK |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.2B |
| IPO Year | 2026 | 2018 |
| Metric | MWH | SRRK |
|---|---|---|
| Price | $26.86 | $44.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $40.91 | ★ $70.44 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $57.86 | N/A |
| Revenue Next Year | $15.37 | $2,600.24 |
| P/E Ratio | $250.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.30 | $34.25 |
| 52 Week High | $48.40 | $61.76 |
| Indicator | MWH | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 47.28 |
| Support Level | $23.71 | $38.72 |
| Resistance Level | $27.27 | $48.27 |
| Average True Range (ATR) | 1.79 | 2.38 |
| MACD | 0.48 | 0.54 |
| Stochastic Oscillator | 72.74 | 28.23 |
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.